Online inquiry

IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2186MR)

This product GTTS-WQ2186MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL15RA gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001243539.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3601
UniProt ID Q13261
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2186MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13116MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ14864MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ149MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6048MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ3896MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ7594MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ3241MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ5736MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW